The only FDA approved test to predict a urothelial carcinoma patient’s response to IMFINZI™* (durvalumab)
Using an approved assay to determine PD-L1 status for immunotherapy options is important. VENTANA PD-L1 (SP263) Assay equips pathologists by
- Identifying urothelial carcinoma patients most likely to benefit from IMFINZI™ (durvalumab)
- Providing robust PD-L1 staining in both tumor cells (TC) and tumor-infiltrating immune cells (IC)
* IMFINZI™ (durvalumab) is a trademark of AstraZeneca Pharmaceutical Company. All rights reserved.